Harborside


Aion Therapeutic Inc.

CNSX: AION


Canadian symbol: AION.CN
US symbol: ANTCF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 2.13M
Enterprise Value 2.77M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)4.79
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.38

Trading Information

Stock Price History

Beta (5Y Monthly) 0.96
52-Week Change 3-83.33%
S&P500 52-Week Change 3-5.12%
52 Week High 30.0950
52 Week Low 30.0150
50-Day Moving Average 30.0214
200-Day Moving Average 30.0305

Share Statistics

Avg Vol (3 month) 3189.48k
Avg Vol (10 day) 3197.51k
Shares Outstanding 5141.8M
Implied Shares Outstanding 6N/A
Float 8109.48M
% Held by Insiders 124.22%
% Held by Institutions 10.00%
Shares Short (Apr 13, 2022) 422.01k
Short Ratio (Apr 13, 2022) 40.08
Short % of Float (Apr 13, 2022) 4N/A
Short % of Shares Outstanding (Apr 13, 2022) 40.02%
Shares Short (prior month Mar 14, 2022) 415.64k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Apr 29, 2021
Most Recent Quarter (mrq)Jan 30, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-40.61%
Return on Equity (ttm)-417.26%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-1.5k
EBITDA -2.06M
Net Income Avi to Common (ttm)-7.46M
Diluted EPS (ttm)-0.0560
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.85k
Total Cash Per Share (mrq)0
Total Debt (mrq)643.8k
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.15
Book Value Per Share (mrq)-0.00

Cash Flow Statement

Operating Cash Flow (ttm)-2.05M
Levered Free Cash Flow (ttm)179.9k

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
AION.CN
Aion Therapeutic
6 months ago
AION.CN
Aion Therapeutic
10 months ago
AION.CN
Aion Therapeutic
1 year ago
AION.CN
Aion Therapeutic
1 year ago
AION.CN
Aion Therapeutic
1 year ago
AION.CN
Aion Therapeutic
1 year ago
AION.CN
Aion Therapeutic
1 year ago
AION.CN
Aion Therapeutic
1 year ago
AION.CN
Aion Therapeutic
1 year ago
AION.CN
Aion Therapeutic
1 year ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
2 years ago
AION.CN
Aion Therapeutic
3 years ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
24.22%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Aion Therapeutic Inc.


Aion Therapeutic's Dr. De La Haye to Speak at the CanEx Psychedelics Summit

Aion Therapeutic’s Dr. De La Haye to Speak at the CanEx Psychedelics Summit

TORONTO, July 14, 2021 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that Dr. Winston De La Haye, Medical Director of the Aion International Center for Psychedelic Psychiatry in Jamaica (the "Center"), will be speaking at the international CanEx Psychedelics Summit in Montego Bay, Jamaica, takin... Read More...
Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways

Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways

LONDON and TORONTO, May 18, 2021 - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased ... Read More...
Aion Therapeutic's Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells

Aion Therapeutic’s Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells

TORONTO, April 21, 2021 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ br... Read More...
Aion Therapeutic Engages KCSA Strategic Communications as Corporate Communications Counsel

Aion Therapeutic Engages KCSA Strategic Communications as Corporate Communications Counsel

TORONTO, April 12, 2021 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") today announced that it has retained KCSA Strategic Communications ("KCSA"), a leading New York City-based communications firm. KCSA will work with management to create a comprehensive, strategic communications program to lead the Company's p... Read More...
Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)

Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)

TORONTO, March 11, 2021 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer,... Read More...
Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer

Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer

Dr. Fritsche has also been appointed Chief Science Officer of AI Pharma, a wholly-owned subsidiary of Aion TherapeuticToronto, Ontario--(Newsfile Corp. - September 10, 2020) - Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas... Read More...
Osoyoos Announces Closing of Acquisition of AI Pharmaceuticals Jamaica Limited

Osoyoos Announces Closing of Acquisition of AI Pharmaceuticals Jamaica Limited

Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it completed its previously announced acquisition of AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a company engaged in the research and development of cannabis (cannabinoids) and mushrooms (psilocin)... Read More...
Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited

Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited

Toronto, Ontario--(Newsfile Corp. - June 26, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it has agreed to acquire 100% of the shares (the "Acquisition") of 1196691 B.C. Ltd. d/b/a "PCAI Pharma" (the "Parent") the parent company that holds 100% of the shares of AI Pharmaceuticals Jamaica Limit... Read More...
Osoyoos Enters into Equipment Lease and Joint-Venture Agreement; Provides Corporate Update

Osoyoos Enters into Equipment Lease and Joint-Venture Agreement; Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - April 21, 2020) -  Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has entered into an equipment lease (the "Equipment Lease") and a joint-venture agreement (the "JV Agreement") with 2623942 Ontario Limited (the "Licensed Producer"). Furthermore, the Compan... Read More...
Osoyoos Announces Debt Settlement

Osoyoos Announces Debt Settlement

Toronto, Ontario--(Newsfile Corp. - September 23, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announces that it has entered into a debt settlement agreement with an arm's length creditor. The agreement reduces the Company's liabilities by $750,000 and improves the Company's financial position with respect to both... Read More...
Osoyoos Resumes Trading

Osoyoos Resumes Trading

Toronto, Ontario--(Newsfile Corp. - September 5, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company"), a cannabinoid-focused processing and extraction company, is pleased to announce that, further to its press release of September 4, 2019, it has been advised by the Canadian Securities Exchange that trading in its common ... Read More...
Leo Acquisitions and CBx Brands Announce Letter of Intent for Proposed Qualifying Transaction

Leo Acquisitions and CBx Brands Announce Letter of Intent for Proposed Qualifying Transaction

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.TORONTO, July 26, 2019 -- Leo Acquisitions Corp. (LEQ-H.V) (“Leo” or the “Company”) and CBx Brands Inc. (“CBx”) are pleased to announce that they have entered into a letter of intent (the “LOI”), dated July 10, 2019, pursuant to which the Company and ... Read More...
Osoyoos Business Updates

Osoyoos Business Updates

Toronto, Ontario--(Newsfile Corp. - May 23, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) (the "Company") announces that the Board of Directors has secured extended and improved terms of a loan note initially payable on March 15, 2020, to a founder and former Director of the Company.The principal amount of one million dollars ($1,000,000 CAD),... Read More...
Osoyoos Cannabis Announces Non-Binding Letter of Intent to Continue as Anahit International Following Reverse Take Over

Osoyoos Cannabis Announces Non-Binding Letter of Intent to Continue as Anahit International Following Reverse Take Over

Toronto, Ontario--(Newsfile Corp. - May 16, 2019) - Osoyoos Cannabis Inc. (CSE:OSO) ("Osoyoos" or the "Company") and Anahit International Corp. ("Anahit" or "Target") are pleased to announce today that they have entered into a non-binding letter of intent ("LOI"), which subject to, among other things, due diligence of each party, the nego... Read More...
Coming Soon.

Delayed data (1h)


Share this page